Routine screening of the optic nerve and macula is not recommended by any major clinical practice guidelines for methotrexate, in stark contrast to drugs like hydroxychloroquine where such monitoring is standard

The following blog post summarizes the current evidence on ophthalmologic monitoring for patients on long-term methotrexate therapy, with a focus on optic nerve and macular evaluation. Ophthalmologic Monitoring in Long-Term Methotrexate Therapy: Current Evidence and Recommendations Understanding Methotrexate-Related Ocular Toxicity Methotrexate (MTX) is a widely used immunosuppressive and antineoplastic agent for conditions including rheumatoid arthritis, psoriasis, [juvenile idiopathic arthritis](https://www.openevidence.com/rare-disease/juvenile-idiopathic-arthritis), and various malignancies. While the drug's hematologic, hepatic, and pulmonary toxicities are well-established and routinely monitored, ocular complications remain less well-characterized and are not part of standard monitoring protocols for most indications. What We Know About Ocular Effects The FDA drug label for methotrexate lists several ophthalmologic adverse reactions, including conjunctivitis, serious visual changes of unknown etiology, blurred vision, transient blindness, and optic neuropathy. However, these effects are reported as post-marketing surveillance data, making it difficult to establish precise incidence rates. Eye discomfort was reported in controlled trials of rheumatoid arthritis patients receiving 7.5-15 mg weekly doses, though specific rates were not quantified beyond being classified as "less common." More concerning, optic neuropathy is listed among post-marketing adverse reactions, though the FDA notes that reliable frequency estimates cannot be established from voluntary reporting systems. The Evidence on Optic Neuropathy A notable 2005 case report described reversible bilateral optic neuropathy in a 66-year-old woman taking low-dose oral methotrexate (2.5 mg three times weekly) for rheumatoid arthritis. The patient developed progressive vision loss with dense central scotomas and color vision defects after 10 months of therapy without folic acid supplementation. Her serum folate was markedly reduced at 1.6 ng/mL (normal >4 ng/mL). Complete visual recovery occurred after discontinuing methotrexate and initiating folic acid supplementation, suggesting a folate-mediated mechanism. Recent pharmacovigilance data from 2025 analyzing over 130,000 methotrexate-related adverse event reports in the FAERS database from 2004-2024 did not identify optic nerve or macular toxicity as prominent signals, though immune system disorders showed the strongest reporting signal overall. A 2024 study examining methotrexate neurotoxicity found that 5.22% of 498 patients receiving MTX exhibited neurotoxic effects, predominantly encephalopathy and encephalomyelopathy. While this study focused on central nervous system toxicity rather than optic nerve pathology specifically, it underscores that neurologic complications can occur even with standard dosing regimens. Macular Toxicity: Limited Evidence Unlike hydroxychloroquine, which has well-documented macular toxicity requiring regular screening, methotrexate does not appear to have a similar association with macular damage. The FDA label mentions "serious visual changes of unknown etiology" but does not specifically identify macular pathology. A 2022 Cochrane review comparing methotrexate to mycophenolate for non-infectious uveitis examined macular edema as an outcome measure. In a subgroup of 35 patients with baseline macular edema, 5 of 22 methotrexate-treated patients and 6 of 13 mycophenolate-treated patients had residual macular edema at six months. However, this study evaluated methotrexate as a treatment for uveitis-related macular edema, not as a cause of macular toxicity. Current Monitoring Guidelines: The Gap in Ophthalmologic Screening Notably, current clinical practice guidelines do not recommend routine ophthalmologic monitoring for patients on chronic methotrexate therapy for non-neoplastic indications. The 2020 Joint American Academy of Dermatology-National Psoriasis Foundation Guidelines for psoriasis management recommend baseline and ongoing monitoring including CBC, liver function tests every 3-6 months, hepatitis B and C screening, and [tuberculosis](https://www.openevidence.com/rare-disease/tuberculosis) testing, but make no mention of ophthalmologic evaluation. Similarly, the 2021 American College of Rheumatology Guidelines for juvenile idiopathic arthritis specify monitoring CBC and liver function tests at baseline, 1-2 months after starting, and every 3-4 months thereafter for methotrexate, but do not include eye examinations. In contrast, these same guidelines recommend baseline and yearly eye examinations for hydroxychloroquine, highlighting the distinction between drugs with established ocular toxicity profiles and those without. The 2012 American College of Chest Physicians Guidelines for monitoring immunosuppressive drugs in lung disease patients recommend CBC, liver function, and renal function monitoring every 4-12 weeks for methotrexate but do not include ophthalmologic screening. Clinical Implications and Recommendations Based on current evidence, routine ophthalmologic screening specifically for methotrexate toxicity is not supported by published guidelines or robust epidemiologic data. The absence of such recommendations stands in stark contrast to drugs like hydroxychloroquine, where retinal toxicity is well-documented and screening protocols are clearly defined. However, clinicians should maintain awareness of potential ocular complications, particularly: Folic acid supplementation is critical. The case of reversible optic neuropathy associated with folate deficiency underscores the importance of routine folic acid supplementation (typically 1 mg daily) in all patients receiving methotrexate. Symptom-directed evaluation. Patients reporting new visual symptoms—including blurred vision, visual field defects, or color vision changes—should be promptly referred for comprehensive ophthalmologic evaluation. Consider baseline screening in high-risk patients. While not guideline-recommended, clinicians may consider baseline ophthalmologic examination in patients with pre-existing visual complaints or risk factors for optic neuropathy, particularly if folic acid supplementation is not being used. Distinguish from other causes. Visual symptoms in patients on methotrexate may be related to the underlying disease (particularly in rheumatoid arthritis with associated scleritis or uveitis), concurrent medications, or unrelated conditions rather than methotrexate toxicity itself. The Bottom Line Unlike hydroxychloroquine, methotrexate does not have a well-established pattern of optic nerve or macular toxicity that would warrant routine ophthalmologic screening in asymptomatic patients. Current evidence consists primarily of case reports and post-marketing surveillance data, with no major clinical practice guidelines recommending regular eye examinations for patients on chronic methotrexate therapy. The focus of methotrexate monitoring should remain on hematologic, hepatic, and renal parameters as outlined in current guidelines, with folic acid supplementation to mitigate folate-dependent toxicities. Ophthalmologic evaluation should be pursued when patients develop visual symptoms, but routine screening of the optic nerve and macula is not currently evidence-based practice for methotrexate therapy. This blog post synthesizes the current evidence on ophthalmologic monitoring for patients receiving long-term methotrexate therapy. The key finding is that routine screening of the optic nerve and macula is not recommended by any major clinical practice guidelines for methotrexate, in stark contrast to drugs like hydroxychloroquine where such monitoring is standard.[1][2] The evidence base consists primarily of case reports and post-marketing surveillance data. The FDA label lists optic neuropathy, blurred vision, and "serious visual changes of unknown etiology" as adverse reactions, but these are voluntary reports without reliable incidence data.[3][4] A notable 2005 case report described reversible bilateral optic neuropathy associated with low-dose methotrexate and folate deficiency, which resolved completely with drug discontinuation and folic acid supplementation.[5] Recent large-scale pharmacovigilance studies from 2024-2025 analyzing over 130,000 adverse event reports did not identify optic nerve or macular toxicity as prominent safety signals.[6] A 2024 study found that 5.22% of methotrexate patients experienced neurotoxicity, but this primarily manifested as encephalopathy rather than optic neuropathy.[7] Current monitoring guidelines from the American Academy of Dermatology, American College of Rheumatology, and American College of Chest Physicians all recommend regular CBC and liver function monitoring but do not include ophthalmologic screening.[1][8][2] This contrasts sharply with hydroxychloroquine, where annual eye examinations are standard.[1] The clinical takeaway is that folic acid supplementation is essential to prevent folate-mediated toxicities, and ophthalmologic evaluation should be pursued for symptomatic patients, but routine screening of asymptomatic patients is not currently supported by evidence or guidelines. References 1. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging. Onel KB, Horton DB, Lovell DJ, et al. Arthritis Care & Research. 2022;74(4):505-520. doi:10.1002/acr.24839. 2. Joint American Academy of Dermatology-National Psoriasis Foundation Guidelines of Care for the Management of Psoriasis With Systemic Nonbiologic Therapies. Menter A, Gelfand JM, Connor C, et al. Journal of the American Academy of Dermatology. 2020;82(6):1445-1486. doi:10.1016/j.jaad.2020.02.044. 3. Methotrexate. Food and Drug Administration. Updated date: 2024-09-05. 4. Methotrexate. Food and Drug Administration. Updated date: 2025-09-22. 5. Reversible Optic Neuropathy Associated With Low-Dose Methotrexate Therapy. Clare G, Colley S, Kennett R, Elston JS. Journal of Neuro-Ophthalmology : The Official Journal of the North American Neuro-Ophthalmology Society. 2005;25(2):109-12. doi:10.1097/01.wno.0000166061.73483.ce. 6. Adverse Drug Reactions Related to Methotrexate: A Real-World Pharmacovigilance Study Using the FAERS Database From 2004 to 2024. Liu S, Yuan Z, Rao S, et al. Frontiers in Immunology. 2025;16:1586361. doi:10.3389/fimmu.2025.1586361. 7. Potential Neurotoxicity Associated With Methotrexate. Apiraksattayakul N, Jitprapaikulsan J, Sanpakit K, Kumutpongpanich T. Scientific Reports. 2024;14(1):18548. doi:10.1038/s41598-024-69263-0. 8. Monitoring of Nonsteroidal Immunosuppressive Drugs in Patients With Lung Disease and Lung Transplant Recipients: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Baughman RP, Meyer KC, Nathanson I, et al. Chest. 2012;142(5):e1S-e111S. doi:10.1378/chest.12-1044.